Determining the optimal SARS-CoV-2 mRNA vaccine dosing interval for maximum immunogenicity
M. Asamoah-Boaheng, D. M. Goldfarb, M. Prusinkiewicz, L. Golding, M. E. Karim, V. Barakauskas, N. Wall, A. N. Jassem, A. C. Marquez, C. MacDonald, S. F. O'Brien, P. Lavoie, B. Grunau
This study finds that longer SARS-CoV-2 vaccine dosing intervals (≥30 days) are associated with higher antibody concentrations and viral neutralization at 6 months post-first dose.
bioRxiv · Mar 1, 2022Microbiology